Synthetic lethality as an engine for cancer drug target discovery

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Genetically targeted cancer therapies have primarily focused on mutated gene products.
• Conventional approaches for identifying new druggable cancer targets are becoming limited.
• Many cancer drivers, including undruggable oncogenes and tumor suppressor genes, remain untargeted.

Purpose of the Study:

• To explore functional genomic screening based on synthetic lethality for novel cancer target discovery.
• To leverage recent advances like CRISPR-based gene editing for systematic screens.
• To identify the next wave of genetic cancer targets for therapeutic development.

Main Methods:

• Utilizing the concept of synthetic lethality for target identification.
• Employing CRISPR-based gene editing for systematic functional genomic screens in human cancers.
• Analyzing genetic dependencies to uncover potential therapeutic targets.

Main Results:

• Demonstrated the potential of functional genomic screening to identify novel cancer targets.
• Showcased the feasibility of systematic synthetic lethality screens in human cancer models.
• Highlighted the capacity of these approaches to address previously untargeted cancer drivers.

Conclusions:

• Functional genomic screening via synthetic lethality is a promising strategy for next-generation cancer target discovery.
• This approach can overcome limitations of traditional mutational analysis and target undruggable or loss-of-function cancer drivers.
• Advances in gene editing technologies facilitate the systematic identification of synthetic lethal targets, paving the way for new cancer medicines.